TJ004309
Phase 2Small molecule
TJ004309 is one of 33 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Phase 3
Aromasin
PfizerPhase 3
Naropin
FFresenius Kabi Oncology Ltd.
Phase 3
Rina-S
GenmabPhase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Azenosertib
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
JSKN003
JJiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
Doxorubicin HCL Liposome
AAccelerated Community Oncology Research Network
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metastatic Cancer2 trials
Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TJ004309. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- II-Mab Biopharma US Limited